The potential role of fowlpox virus in rational vaccine design

References

• Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc. Natl Acad. Sci. USA93(21), 11341–11348 (1996).
   PubMed Web of Science ®Google Scholar
• Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat. Med.10(11), 1177–1185 (2004).
   PubMed Web of Science ®Google Scholar
• Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev.199, 227–250 (2004).
   PubMed Web of Science ®Google Scholar
• Doeuk DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell124, 677–681 (2005).
   Google Scholar
• Moss B. Poxviridae and their replication Fields BN, Kea DM (Eds), Raven Press, Ltd, NY, USA (1990).
   Google Scholar
• Smith SA, Kotwal GJ. Immune responses to poxvirus infections in various animals. Crit. Rev. Microbiol.28(3), 149–185 (2002).
   Web of Science ®Google Scholar
• Boulanger D, Smith T, Skinner M. Morphogenesis and release of fowlpox virus. J. Gen. Virol.81(3), 675–687 (2000).
   PubMed Web of Science ®Google Scholar
• Fenner F. Adventures with poxviruses of vertebrates. FEMS Microbiol. Rev.24(2), 123–133 (2000).
   PubMed Web of Science ®Google Scholar
• Afonso CL, Tulman ER, Delhon G et al. Genome of crocodilepox virus. J. Virol.80(10), 4978–4991 (2006).
   Google Scholar
• Boulanger D, Green P, Jones B et al. Identification and characterisation of three immunodominant structural proteins of fowlpox virus. J. Virol.76(19), 9844–9855 (2002).
   PubMed Web of Science ®Google Scholar
• Afonso CL, Tulman ER, Lu Z et al. The genome of fowlpox virus. J. Virol.74(8), 3815–3831 (2000).
   PubMed Web of Science ®Google Scholar
• Seet BT, Johnston JB, Brunetti CR et al. Poxviruses and immune evasion. Ann. Rev. Immunol.21, 377–423 (2003).
   PubMedGoogle Scholar
• Taylor J, Weinburg R, Languet B et al. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine6(6), 497–503 (1988).
   PubMed Web of Science ®Google Scholar
• Singh P, Schnitzlein WM, Tripathy DN. Reticuloendotheliosis virus sequences within the genomes of field strains of fowlpox virus display variability. J. Virol.77(10), 5855–5862 (2003).
   PubMed Web of Science ®Google Scholar
• Singh P, Kim T-J, Tripathy DN. Re-emerging fowlpox: evaluation of isolates from vaccinated flocks. Avian Pathol.29, 449–455 (2000).
   PubMed Web of Science ®Google Scholar
• Hertig C, Coupar BE, Gould AR et al. Field and vaccine strains of fowlpox virus carry integrated sequences from the avian retrovirus, reticuloendotheliosis virus. Virology235(2), 367–376 (1997).
   PubMed Web of Science ®Google Scholar
• Laidlaw SM, Skinner MA. Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of fowlpox virus, with those of virulent American and European viruses. J. Gen. Virol.85(Pt 2), 305–322 (2004).
   PubMed Web of Science ®Google Scholar
• Webster DP, Dunachie S, McConkey S et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine24(15), 3026–3034 (2006).
   PubMed Web of Science ®Google Scholar
• Skinner MA, Laidlaw SM, Eldaghayes I et al. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev. Vaccines4(1), 63–76 (2005).
   PubMed Web of Science ®Google Scholar
• Brown M, Davies DH, Skinner MA et al. Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors. Cancer Gene Ther.6(3), 238–245 (1999).
   PubMed Web of Science ®Google Scholar
• McFadden G. Poxvirus tropism. Nat. Rev. Microbiol.3(3), 201–213 (2005).
   PubMed Web of Science ®Google Scholar
• Kwak H, Horig H, Kaufman HL. Poxviruses as vectors for cancer immunotherapy. Curr. Opin. Drug Discov. Develop.6(2), 161–168 (2003).
   Google Scholar
• Somogyi P, Fraser J, Skinner MA. Fowlpox virus host range restriction: gene expression, DNA replication and morphogenesis in nonpermissive mammalian cells. Virology197(1), 439–444 (1993).
   PubMed Web of Science ®Google Scholar
• Chahroudi A, Chavan R, Kozyr N et al. Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J. Virol.79(16), 10397–10407 (2005).
   PubMed Web of Science ®Google Scholar
• Schneider-Schaulies J. Cellular receptors for viruses: links to tropism and pathogenesis. J. Gen. Virol.81(Pt 6), 1413–1429 (2000).
   PubMedGoogle Scholar
• Johnston JB, McFadden G. Poxvirus immunomodulatory strategies: current perspectives. J. Virol.77(11), 6093–6100 (2003).
   PubMed Web of Science ®Google Scholar
• Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Ann. Rev. Biochem.68, 383–424 (1999).
   Google Scholar
• Thornberry NA, Bull HG, Calaycay JR et al. A novel heterodimeric cysteine protease is required for interleukin-1 β processing in monocytes. Nature356(6372), 768–774 (1992).
   PubMed Web of Science ®Google Scholar
• Zhou Q, Snipas S, Orth K et al. Target protease specificity of the viral serpin crmA. J. Biol. Chem.272(12), 7797–7800 (1997).
   PubMedGoogle Scholar
• Turner PC, Moyer RW. Control of apoptosis by poxviruses. Semin. Virol.8(6), 453–469 (1998).
   Google Scholar
• Alcami A, Symons J, Khanna A et al. Poxviruses: capturing cytokines and chemokines. Semin. Virol.8(5), 419–427 (1998).
   Google Scholar
• Puehler F, Schwartz H, Waidners B et al. An interferon-γ binding protein of novel structure encoded by the fowlpox virus. J. Biol. Chem.278(9), 6905–6911 (2003).
   PubMed Web of Science ®Google Scholar
• Mossman K, Upton C, Buller RML et al. Specis specificity of ectromelia virus and vaccinia virus interferon-γ binding proteins. Virology208(2), 762–769 (1995).
   Google Scholar
• Gherardi MM, Ramirez JC, Esteban M. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J. Gen. Virol.84(8), 1961–1972 (2003).
   PubMed Web of Science ®Google Scholar
• Shtrichman R, Samuel CE. The role of γ interferon in antimicrobial immunity. Curr. Opin. Microbiol.4(3), 251–259 (2001).
   PubMed Web of Science ®Google Scholar
• Wang F, Ma Y, Barrett JW et al. Disruption of erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol.5(12), 1266–1274 (2004).
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Hengartner H. On immunity against infections and vaccines: credo 2004. Scand. J. Immunol.60(1–2), 9–13 (2004).
   PubMed Web of Science ®Google Scholar
• Hutchings CL, Gilbert SC, Hill AV et al. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J. Immunol.175(1), 599–606 (2005).
   PubMed Web of Science ®Google Scholar
• Ramshaw IA, Ramsay AJ. The prime–boost strategy: exciting prospects for improved vaccination. Immunol. Today21(4), 163–165 (2000).
   PubMedGoogle Scholar
• Polo JM, Dubensky TW Jr. Virus-based vectors for human vaccine applications. Drug Discov. Today7(13), 719–727 (2002).
   PubMed Web of Science ®Google Scholar
• Smith CL, Mirza F, Pasquetto V et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia ankara. J. Immunol.175(12), 8431–8437 (2005).
   PubMed Web of Science ®Google Scholar
• Harrington LE, Most R Rv, Whitton JL et al. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol.76(7), 3329–3337 (2002).
   PubMed Web of Science ®Google Scholar
• Ockenhouse CF, Sun PF, Lanar DE et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-PF7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis.177(6), 1664–1673 (1998).
   PubMed Web of Science ®Google Scholar
• Drexler I, Staib C, Kastenmuller W et al. Identification of vaccinia virus epitope-specific HLA-a*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl Acad. Sci. USA100(1), 217–222 (2003).
   PubMedGoogle Scholar
• Tscharke DC, Karupiah G, Zhou J et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med.201(1), 95–104 (2005).
   PubMed Web of Science ®Google Scholar
• Oseroff C, Kos F, Bui HH et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc. Natl Acad. Sci. USA102(39), 13980–13985 (2005).
   PubMedGoogle Scholar
• Slifka MK. The future of smallpox vaccination: is MVA the key? Med. Immunol.4(1), 2 (2005).
   PubMedGoogle Scholar
• Souza AP, Haut L, Reyes-Sandoval A et al. Recombinant viruses as vaccines against viral diseases. Braz. J. Med. Biol. Res.38(4), 509–522 (2005).
   PubMed Web of Science ®Google Scholar
• Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl Acad. Sci. USA93(21), 11349–11353 (1996).
   PubMed Web of Science ®Google Scholar
• Coupar BEH, Teo T, Boyle DB. Restriction endonuclease mapping of the fowlpox virus genome. Virology179(1), 159–167 (1990).
   PubMed Web of Science ®Google Scholar
• Robinson HL, Montefiori DC, Johnson RP et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med.5(5), 526–534 (1999).
   PubMed Web of Science ®Google Scholar
• Kent SJ, Dale CJ, Ranasinghe C et al. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine23(42), 5009–5021 (2005).
   PubMed Web of Science ®Google Scholar
• Letvin NL. Progress toward an HIV vaccine. Ann. Rev. Med.56, 213–223 (2005).
   PubMed Web of Science ®Google Scholar
• Vazquez Blomquist D, Green P, Laidlaw SM et al. Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide. Viral Immunol.15(2), 337–356 (2002).
   Google Scholar
• Dale CJ, Zhao A, Jones SL et al. Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-γ. J. Med. Primatol.29(3–4), 240–247 (2000).
   Google Scholar
• Dale CJ, De Rose R, Stratov I et al. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J. Virol.78(24), 13819–13828 (2004).
   PubMed Web of Science ®Google Scholar
• Kent SJ Zhao A, Best SJ et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol.72(12), 10180–10188 (1998).
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Imoukhuede EB, Keating S et al. Phase 1 evaluation of 3 highly immunogenic prime–boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis.189(12), 2213–2219 (2004).
   PubMed Web of Science ®Google Scholar
• Webster DP, Dunachie S, Vuola JM et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl Acad. Sci. USA102(13), 4836–4841 (2005).
   PubMed Web of Science ®Google Scholar
• Yang S, Hodge JW, Grosenbach DW et al. Vaccines with enhanced costimulation maintain high avidity memory CTL. J. Immunol.175(6), 3715–3723 (2005).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol.23(4), 720–731 (2005).
   PubMed Web of Science ®Google Scholar
• Dipaola R, Plante M, Kaufman H et al. A Phase I trial of pox PSA vaccines (PROSTVAC(r)-VF) with B7–1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in patients with prostate cancer. J. Transl. Med.4, 1 (2006).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern cooperative oncology group. J. Clin. Oncol.22(11), 2122–2132 (2004).
   PubMed Web of Science ®Google Scholar
• Carroll MW, Moss B. Poxviruses as expression vectors. Curr. Opin. Biotechnol.8(5), 573–577 (1997).
   PubMed Web of Science ®Google Scholar
• Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine6(6), 466–468 (1988).
   PubMed Web of Science ®Google Scholar
• Bembridge GP, Lopez JA, Cook R et al. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or γ interferon. J. Virol.72(5), 4080–4087 (1998).
   PubMed Web of Science ®Google Scholar
• Zhu M, Terasawa H, Gulley J et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res.61(9), 3725–3734 (2001).
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Aldrich W, Allen KO et al. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma. Int. J. Cancer.113(3), 406–414 (2005).
   Google Scholar
• Grosenbach DW, Barrientos JC, Schlom J et al. Synergy of vaccine strategies to amplify antigen-sepcific immune responses and antitumour effects. Cancer Res.61(11), 4497–4505 (2001).
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res.59(22), 5800–5807 (1999).
   PubMed Web of Science ®Google Scholar
• Hodge JW, Rad AN, Grosenbach DW et al. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J. Natl Cancer Inst.92(15), 1228–1239 (2000).
   PubMed Web of Science ®Google Scholar
• Marshall E. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science311(5768), 1688–1689 (2006).
   PubMedGoogle Scholar
• Evans EJ, Esnouf RM, Manso-Sancho R et al. Crystal structure of a soluble CD28-FAb complex. Nat. Immunol.6(3), 271–279 (2005).
   PubMed Web of Science ®Google Scholar
• Hopkin M. Can super-antibody drugs be tamed? Nature440, 855–856 (2006).
   PubMed Web of Science ®Google Scholar
• Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Ann. Rev. Immunol.15, 297–322 (1997).
   PubMed Web of Science ®Google Scholar
• Reali E, Canter D, Zeytin H et al. Comparative studies of avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine23(22), 2909–2921 (2005).
   PubMed Web of Science ®Google Scholar
• Dale CJ, De Rose R, Wilson KM et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN-γ or IL-12. Vaccine23(2), 188–197 (2004).
   PubMed Web of Science ®Google Scholar
• Jackson RJ, Ramsay AJ, Christensen CD et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol.75(3), 1205–1210 (2001).
   PubMed Web of Science ®Google Scholar
• Mullbacher A, Lobigs M. Creation of killer poxvirus could have been predicted. J. Virol.75(18), 8353–8355 (2001).
   Google Scholar
• Aung S, Graham B. IL-4 diminishes perforin-mediated and increases fas ligand-mediated cytotoxicity in vivo.J. Immunol.164(7), 3487–3493 (2000).
   PubMedGoogle Scholar
• Estcourt MJ, Ramsay AJ, Brooks A et al. Prime–boost immunisation generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int. Immunol.14(1), 31–37 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Hannan CM, Gilbert SC et al. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol.172(5), 3094–3100 (2004).
   PubMed Web of Science ®Google Scholar
• Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol.54(Pt 1), 1–13 (1989).
   PubMedGoogle Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell124(4), 849–863 (2006).
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell124(4), 783–801 (2006).
   PubMed Web of Science ®Google Scholar
• Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science300(5625), 1524–1525 (2003).
   PubMed Web of Science ®Google Scholar
• Germain RN. An innately interesting decade of research in immunology. Nat. Med.10(12), 1307–1320 (2004).
   Google Scholar
• Napolitani G, Rinaldi A, Bertoni F et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol.6(8), 769–776 (2005).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. HIV gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA102(42), 15190–15194 (2005).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime–boost immunization in nonhuman primates. J. Exp. Med.203(5), 1249–1258 (2006).
   PubMed Web of Science ®Google Scholar
• Bowie A, Kiss-Toth E, Symons JA et al. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling. Proc. Natl Acad. Sci. USA97(18), 10162–10167 (2000).
   PubMed Web of Science ®Google Scholar
• Harte MT, Haga IR, Maloney G et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med.197(3), 343–351 (2003).
   PubMed Web of Science ®Google Scholar
• Pincus S, Tartaglia J, Paoletti E. Poxvirus-based vectors as vaccine candidates. Biologicals23(2), 159–164 (1995).
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. From antigen presentation to T-cell activation. Res. Immunol.149(7–8), 626 (1998).
   Google Scholar
• Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Ann. Rev. Immunol.19, 47–64 (2001).
   PubMed Web of Science ®Google Scholar
• Ploegh HL. Immunology. Nothing 'gainst time's scythe can make defense. Science304(5675), 1262–1263 (2004).
   Google Scholar
• Heath WR, Belz GT, Behrens GM et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev.199, 9–26 (2004).
   PubMed Web of Science ®Google Scholar
• Neijssen J, Herberts C, Drijfhout JW et al. Cross-presentation by intercellular peptide transfer through gap junctions. Nature434(7029), 83–88 (2005).
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Coupling and cross-presentation. Nature434(7029), 27–28 (2005).
   Google Scholar
• Zinkernagel RM. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol.32(9), 2385–2392 (2002).
   Google Scholar
• Hickman-Miller HD, Yewdell JW. Youth has its privileges: Maturation inhibits DC cross-priming. Nat. Immunol.7(2), 125–126 (2006).
   Google Scholar
• Wilson NS, Behrens GM, Lundie RJ et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol.7(2), 165–172 (2006).
   PubMed Web of Science ®Google Scholar
• Sigal LJ, Crotty S, Andino R et al. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature398(6722), 77–80 (1999).
   PubMed Web of Science ®Google Scholar
• Shen X, Wong SB, Buck CB et al. Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J. Immunol.169(8), 4222–4229 (2002).
   PubMedGoogle Scholar
• Norbury CC, Malide D, Gibbs JS et al. Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo.Nat. Immunol.3(3), 265–271 (2002).
   PubMed Web of Science ®Google Scholar
• Truckenmiller ME, Norbury CC. Viral vectors for inducing CD8+ T cell responses. Expert Opin. Biol. Ther.4(6), 861–868 (2004).
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Haeryfar SM. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Ann. Rev. Immunol.23, 651–682 (2005).
   PubMed Web of Science ®Google Scholar